Botox for Chronic Migraine in St. Louis

Botox does not treat a migraine that has already started. It is a preventive treatment, given on a schedule to reduce how many headache days you have each month. It works by blocking the release of neurotransmitters involved in pain signaling at the nerve endings around the head and neck, which reduces the sensitization that keeps the migraine cycle running. The cosmetic effect is incidental and not the goal.

This matters more than most patients are told. Botox is FDA-approved for chronic migraine, defined as 15 or more headache days per month, of which at least 8 have migraine features, sustained over three months. It is not approved for episodic migraine, and the trials did not show benefit in that group. If you have fewer than 15 headache days a month we will say so and look at other options rather than treat you with something the evidence does not support. Keeping a headache diary before your consultation is the single most useful thing you can do.

We follow the PREEMPT protocol: 31 injections of a fixed dose distributed across seven muscle areas of the forehead, temples, back of the head, neck and upper shoulders. The needles are very fine and the whole appointment takes about fifteen minutes. No sedation is used and you drive yourself home. Treatment repeats every twelve weeks.

Benefit builds rather than appears. Many patients notice little after the first round and a clearer reduction after the second or third, which is why the protocol is designed as a series. Neck soreness for a few days is the most common side effect. If your headaches have a strong cluster or facial-pain component we may combine or compare this with a sphenopalatine ganglion block, and persistent head and neck pain from the cervical spine is evaluated separately, because it does not respond to Botox in the same way.

Botulinum toxin type A is best known for blocking acetylcholine release at the neuromuscular junction, which is how it relaxes muscle. That is not the mechanism that matters in migraine. The toxin cleaves SNAP-25, a protein in the SNARE complex that vesicles require in order to fuse with the cell membrane and release their contents. Sensory neurons use the same machinery.

Blocking it in peripheral trigeminal sensory endings reduces the release of neuropeptides including CGRP and substance P. Those neuropeptides drive peripheral sensitization, and sustained peripheral input is what maintains central sensitization in the trigeminocervical complex, the state in which ordinary stimuli begin to register as painful. Reducing the peripheral drive is how a drug injected into scalp and neck tissue changes a condition generated centrally.

This also explains the twelve-week interval. It reflects the time required for the neuron to regenerate functional SNAP-25 and restore normal vesicle release, not how long the muscle stays relaxed.

The PREEMPT program tested this in chronic migraine and found a benefit. The same approach studied in episodic migraine did not separate from placebo. That is not a licensing technicality; it reflects the mechanism. If central sensitization is already established, as it is in chronic migraine, reducing the peripheral drive that sustains it has something to act on. In episodic migraine that state is not continuously present, so there is less for the toxin to interrupt between attacks.

It is the clearest example on this site of why we ask for a headache diary before treating. The number of headache days is not paperwork for the insurer. It is the variable that predicts whether the treatment can work at all.